The significance of this paradigm is reflected in encouraging results using BCL-2/BCL-XL targeting BH3-mimetics in combination with agents that down-regulate MCL-1 in murine models of MYC-BCL2 double-hit lymphoma and human DLBCL [13, 14]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.